Positions

Overview

  • My major research interest is in multiple myeloma. I, along with my multiple myeloma colleagues, established an interdisciplinary myeloma clinic in March 2013, which is the first clinic of its kind in Alabama dedicated solely to plasma cell malignancies. I have also represented UAB on the NCCN Multiple Myeloma guidelines panel. My future and ongoing goals include opening and expanding clinical trials for the relapsed/refractory multiple myeloma patient population and to continue to serve the growing multiple myeloma patient population.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia.  33:2266-2275. 2019
    2018 Second primary malignancy after multiple myeloma-population trends and cause-specific mortalityBritish Journal of Haematology.  182:513-520. 2018
    2018 Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple MyelomaBiology of Blood and Marrow Transplantation.  24:1379-1385. 2018
    2018 Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network.  16:11-20. 2018
    2017 Clinical practice guidelines in oncologyJournal of the National Comprehensive Cancer Network.  15:230-269. 2017
    2017 Accuracy of Medicare Claim-based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone MetastasesMedical Care.  55:e144-e149. 2017
    2016 NCCN guidelines® insights multiple myeloma, version 3.2016 featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network.  14:389-400. 2016
    2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresCancer Causes and Control.  27:81-91. 2016
    2016 Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myelomaAmerican Journal of Hematology.  91:101-108. 2016
    2015 Multiple myeloma, version 2.2016: Clinical practice guidelines in oncologyJournal of the National Comprehensive Cancer Network.  13:1398-1435. 2015
    2014 Occult primary, version 3.2014; Featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network.  12:969-974. 2014

    Research Overview

  • Multiple Myeloma, Plasma cell malignancies
  • Principal Investigator On

  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2013 - 2019
  • Private Grant  awarded by ARRAY BIOPHARMA 2015 - 2016
  • Private Grant  awarded by POLARIS GROUP 2012 - 2015
  • Private Grant  awarded by TGEN DRUG DEVELOPMENT SERVICES 2012 - 2015
  • Private Grant  awarded by INCYTE CORPORATION 2012 - 2013
  • Investigator On

  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center 2019 - 2024
  • Private Grant  awarded by REPLIMUNE INC. 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2023
  • Private Grant  awarded by MUNDIPHARMA 2018 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2023
  • Private Grant  awarded by IDERA PHARMACEUTICALS, INC. 2018 - 2023
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL 2018 - 2023
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by Janssen 2018 - 2023
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2022
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION 2017 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2016 - 2021
  • Private Grant  awarded by AMGEN, INC. 2016 - 2021
  • Private Grant  awarded by AMGEN, INC. 2016 - 2021
  • Private Grant  awarded by ELIOS THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2020
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC. 2015 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Private Grant  awarded by GlaxoSmithKline 2012 - 2020
  • Private Grant  awarded by ELIOS THERAPEUTICS 2015 - 2020
  • Private Grant  awarded by AMGEN, INC. 2015 - 2020
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by CYTRX CORPORATION 2014 - 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2019
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2019
  • BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma  awarded by National Marrow Donor Program 2017 - 2019
  • Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)  awarded by VANDERBILT UNIVERSITY 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • Private Grant  awarded by Novartis Pharma AG 2013 - 2018
  • Private Grant  awarded by Novartis Pharma AG 2014 - 2018
  • Private Grant  awarded by Genentech 2011 - 2017
  • Private Grant  awarded by BOSTON SCIENTIFIC CORPORATION 2016 - 2017
  • Private Grant  awarded by MERCK & COMPANY, INC. 2013 - 2017
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2017
  • Private Grant  awarded by NEWLINK GENETICS, INC 2016 - 2017
  • Private Grant  awarded by EMD SERONO 2012 - 2016
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2013 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2011 - 2016
  • Private Grant  awarded by Genentech 2012 - 2015
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC. 2013 - 2015
  • Private Grant  awarded by Genentech 2011 - 2015
  • Education And Training

  • Bachelor of Science or Mathematics in Biology, Southern College 2005
  • Doctor of Medicine, Mercer University 2005
  • UAB Hospital, Internship 2006
  • UAB Hospital, Residency 2008
  • Full Name

  • Kelly Godby